Corcept Therapeutics Competitors

Corcept Therapeutics (NASDAQ:CORT) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Valuation & Earnings

This table compares Corcept Therapeutics and Johnson & Johnson's revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Corcept Therapeutics. Johnson & Johnson is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corcept Therapeutics and Johnson & Johnson's net margins, return on equity and return on assets.

Insider & Institutional Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Corcept Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Corcept Therapeutics and Johnson & Johnson, as provided by MarketBeat.

Corcept Therapeutics presently has a consensus target price of $24.00, suggesting a potential upside of 5.82%. Johnson & Johnson has a consensus target price of $180.6429, suggesting a potential upside of 12.03%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Corcept Therapeutics.

Corcept Therapeutics (NASDAQ:CORT) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Corcept Therapeutics and Pfizer's top-line revenue, earnings per share and valuation.

Pfizer has higher revenue and earnings than Corcept Therapeutics. Pfizer is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corcept Therapeutics and Pfizer's net margins, return on equity and return on assets.

Insider & Institutional Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 67.4% of Pfizer shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.1% of Pfizer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Corcept Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Corcept Therapeutics and Pfizer, as reported by MarketBeat.com.

Corcept Therapeutics currently has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Pfizer has a consensus price target of $38.5714, suggesting a potential upside of 5.39%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Corcept Therapeutics is more favorable than Pfizer.

Summary

Corcept Therapeutics beats Pfizer on 10 of the 14 factors compared between the two stocks.

Corcept Therapeutics (NASDAQ:CORT) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Corcept Therapeutics and Merck & Co., Inc.'s top-line revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Corcept Therapeutics. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corcept Therapeutics and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Insider & Institutional Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Corcept Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Corcept Therapeutics and Merck & Co., Inc., as reported by MarketBeat.com.

Corcept Therapeutics currently has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Merck & Co., Inc. has a consensus price target of $95.9167, suggesting a potential upside of 25.69%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, analysts plainly believe Merck & Co., Inc. is more favorable than Corcept Therapeutics.

Corcept Therapeutics (NASDAQ:CORT) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Corcept Therapeutics and AbbVie's top-line revenue, earnings per share and valuation.

AbbVie has higher revenue and earnings than Corcept Therapeutics. AbbVie is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Corcept Therapeutics and AbbVie's net margins, return on equity and return on assets.

Insider & Institutional Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of AbbVie shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Corcept Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Corcept Therapeutics and AbbVie, as reported by MarketBeat.com.

Corcept Therapeutics currently has a consensus price target of $24.00, suggesting a potential upside of 5.82%. AbbVie has a consensus price target of $115.75, suggesting a potential upside of 7.63%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Corcept Therapeutics.

Eli Lilly and (NYSE:LLY) and Corcept Therapeutics (NASDAQ:CORT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability.

Insider and Institutional Ownership

75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 75.4% of Corcept Therapeutics shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 16.4% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Eli Lilly and and Corcept Therapeutics, as reported by MarketBeat.

Eli Lilly and currently has a consensus price target of $196.40, suggesting a potential upside of 6.46%. Corcept Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Given Eli Lilly and's stronger consensus rating and higher possible upside, equities analysts clearly believe Eli Lilly and is more favorable than Corcept Therapeutics.

Valuation & Earnings

This table compares Eli Lilly and and Corcept Therapeutics' top-line revenue, earnings per share and valuation.

Eli Lilly and has higher revenue and earnings than Corcept Therapeutics. Corcept Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eli Lilly and and Corcept Therapeutics' net margins, return on equity and return on assets.

Volatility and Risk

Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Summary

Eli Lilly and beats Corcept Therapeutics on 9 of the 14 factors compared between the two stocks.

Corcept Therapeutics (NASDAQ:CORT) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and earnings.

Volatility and Risk

Corcept Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Profitability

This table compares Corcept Therapeutics and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Institutional & Insider Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Corcept Therapeutics and Bristol-Myers Squibb, as reported by MarketBeat.com.

Corcept Therapeutics presently has a consensus price target of $24.00, suggesting a potential upside of 5.82%. Bristol-Myers Squibb has a consensus price target of $74.6429, suggesting a potential upside of 19.22%. Given Bristol-Myers Squibb's stronger consensus rating and higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Corcept Therapeutics.

Earnings and Valuation

This table compares Corcept Therapeutics and Bristol-Myers Squibb's gross revenue, earnings per share (EPS) and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Corcept Therapeutics. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Corcept Therapeutics on 8 of the 15 factors compared between the two stocks.